Company Overview
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Key Highlights
- Biotechnology · Healthcare
- Led by Daniel Schmitt
- 12 employees
- Based in Fort Worth, TX
Price History
Loading…
Data from Twelve Data. Prices may be delayed.
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Nov 17
G.17 - Industrial Production and Capacity Utilization
9:15 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
68,303 −4.05%
Ethereum (ETH)
1,933 −3.91%
Solana (SOL)
78 −3.81%
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Fort Worth, TX, US
- Incorporated
- Aug 13, 2024
- Website
- actuatetherapeutics.com
Latest SEC Filings
View All Filings →- Quarterly Report (Form 10-Q)Nov 13, 2026